2004 Highlights

• Net sales growth between 21% and 24%

  • Strong RMS, Pre-Clinical and Clinical organic growth

• Improved margins

  • RMS, Pre-Clinical and Clinical

• Strong EPS growth

• Free cash flow greater than $100 million

Previous slide

Next slide

Back to first slide

View graphic version